Notice Number: NOT-NS-10-002
Key Dates
Release Date: October 16, 2009
Issued by
NIH Blueprint for Neuroscience Research (http://neuroscienceblueprint.nih.gov/) and its member institutes, offices, and centers:
National Center for Research Resources (NCRR) (http://www.ncrr.nih.gov/)
National Eye Institute (NEI) (http://www.nei.nih.gov/)
National Institute on Aging (NIA) (http://www.nia.nih.gov/)
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (http://www.niaaa.nih.gov/)
National Institute of Biomedical Imaging and Bioengineering (NIBIB) (http://www.nibib.nih.gov/)
National Institute of Child Health and Human Development (NICHD) (http://www.nichd.nih.gov/)
National Institute on Drug Abuse (NIDA) (http://www.nida.nih.gov/)
National Institute on Deafness and Other Communication Disorders (NIDCD) (http://www.nidcd.nih.gov/)
National Institute of Dental and Craniofacial Research (NIDCR) (http://www.nidcr.nih.gov/)
National Institute of Environmental Health Sciences (NIEHS) (http://www.niehs.nih.gov/)
National Institute of General Medical Sciences (NIGMS) (http://www.nigms.nih.gov/)
National Institute of Mental Health (NIMH) (http://www.nimh.nih.gov/)
National Institute of Neurological Disorders and Stroke (NINDS) (http://www.ninds.nih.gov/)
National Institute of Nursing Research (NINR) (http://www.ninr.nih.gov/)
Office of Behavioral and Social Sciences Research (OBSSR) (http://obssr.od.nih.gov)
Purpose
The NIH Blueprint for Neuroscience Research (http://neuroscienceblueprint.nih.gov/)
intends to issue a Request for Applications (RFA) to solicit projects for the Blueprint Grand Challenge for New Drugs for Diseases and Disorders of the Nervous System. The goal is to support the development of new small molecule drugs that will transform the treatment of neurological, psychiatric, or other nervous system diseases or conditions. These awards will provide 1) funding to support biological testing of compounds during development and 2) access to technical, infrastructure, and advisory resources to enable investigators to translate promising lead small molecule compounds into drugs that have completed phase 1 clinical trials. Applicants to this RFA must have:
- At least one small molecule compound with strong evidence of biological activity relevant to the intended indication as a starting point for medicinal chemistry optimization.
- A robust, moderate throughput assay of biological activity suitable for testing compounds generated in an iterative medicinal chemistry effort. This assay should be capable of providing robust dose-response data on 20-40 compounds in a 1-2 week cycle.
- Secondary bioassays and models sufficient to evaluate the potential of a drug candidate for the intended indication.
Resources to conduct drug development activities other than bioactivity testing will be provided to the successful applicants by the NIH Blueprint. These include medicinal chemistry optimization, pharmacology and toxicology testing and Phase 1 clinical testing. Successful applicants will retain ownership of the intellectual property for compounds they develop through this program.
This notice is being provided to allow potential applicants sufficient time to develop responsive projects and necessary collaborations. The RFA is expected to be published in the NIH Guide for Grants and Contracts in April 2010 with an anticipated receipt date in August 2010.
This RFA will use the U01 cooperative agreement mechanism.
APPLICATIONS ARE NOT BEING SOLICITED AT THIS TIME.
Inquiries
Interested parties may contact:
Jill Heemskerk Ph.D.
National Institute of Neurological Disorders and Stroke
National Institutes of Health
6001 Executive Boulevard, Room 2229
Bethesda, MD 20892-9525
EXPRESS/COURIER: Rockville, MD 20852
Email: [email protected]
and Human Services (HHS)
